High-performance liquid chromatographic procedure for the determination of a non-nucleoside HIV-1 reverse transcriptase inhibitor in human plasma.
A method for the determination of a non-nucleoside HIV-1 reverse transcriptase inhibitor in human plasma is described. Plasma samples are extracted using phenyl solid-phase extraction columns. The extract is analyzed by high-performance liquid chromatography with a polybutadiene-coated alumina column and a mobile phase of methanol-0.025 M pH 8 dibasic sodium phosphate buffer (1:1, v/v). Detection is based on ultraviolet absorbance at 326 nm. The assay was validated in the concentration range 10-500 ng/ml when 1-ml aliquots of plasma are extracted. The assay has been utilized to support human pharmacokinetic studies.
Woolf
E
E
Merck Sharp and Dohme Research Laboratories, Department of Drug Metabolism, West Point, PA 19486.
Matuszewski
B
B
D000284:Administration, Oral; D000998:Antiviral Agents / Q000097:blood*; D001583:Benzoxazoles / Q000008:administration & dosage / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D054303:HIV Reverse Transcriptase; D006679:HIV Seropositivity / Q000097:blood; D015497:HIV-1 / Q000201:enzymology*; D006358:Hot Temperature; D006801:Humans; D011728:Pyridones / Q000008:administration & dosage / Q000097:blood*; D015203:Reproducibility of Results; D018894:Reverse Transcriptase Inhibitors
D000998:Antiviral Agents; D001583:Benzoxazoles; D011728:Pyridones; D018894:Reverse Transcriptase Inhibitors; C070357:L 697639; D054303:HIV Reverse Transcriptase